Coya Therapeutics: Chardan Capital maintains Buy rating, raises PT to $14 from $14.

viernes, 14 de noviembre de 2025, 8:33 am ET1 min de lectura
COYA--

Coya Therapeutics: Chardan Capital maintains Buy rating, raises PT to $14 from $14.

Coya Therapeutics: Chardan Capital maintains Buy rating, raises PT to $14 from $14.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios